Keyphrases
Gastric Cancer
58%
5-fluorouracil (5-FU)
47%
Chemotherapy
45%
Phase II Trial
39%
Oxaliplatin
38%
Tumor
37%
Adenocarcinoma of the Esophagogastric Junction
36%
Gastroesophageal Junction Cancer
35%
Locally Advanced
35%
Overall Survival
33%
Cisplatin
33%
Docetaxel
31%
Trastuzumab
30%
Esophagogastric Adenocarcinoma
30%
Ramucirumab
30%
Capecitabine
25%
Randomized Phase II Trial
24%
Leucovorin
24%
Fluorouracil
23%
Fluoropyrimidine
22%
Neoadjuvant Chemotherapy
21%
Metastatic Gastric Cancer
21%
Cetuximab
20%
Gastroesophageal Adenocarcinoma
20%
Preoperative Chemotherapy
19%
Paclitaxel
19%
Gastroesophageal Junction
19%
Advanced Gastric Cancer
18%
Histological Response
18%
Programmed Death-ligand 1 (PD-L1)
18%
Advanced or Metastatic
17%
Neoadjuvant
17%
Human Epidermal Growth Factor Receptor 2 (HER2)
16%
Esophageal Cancer
16%
Second-line Treatment
16%
Standard of Care
16%
Nivolumab
15%
Progression-free Survival
15%
Quality of Life
14%
Metastatic Colorectal Cancer (mCRC)
14%
Immune Checkpoint Inhibitors
14%
Perioperative Care
14%
Treatment Options
14%
Treatment Strategy
13%
Stomach Adenocarcinoma
13%
FOLFOX
13%
Elderly Patients
13%
HER2-positive
12%
Phase II Study
12%
Gastroesophageal Cancer
12%
Pharmacology, Toxicology and Pharmaceutical Science
Chemotherapy
100%
Adenocarcinoma
81%
Abdominal Cancer
75%
Malignant Neoplasm
66%
Neoplasm
51%
Fluorouracil
47%
Overall Survival
37%
Oxaliplatin
34%
Folinic Acid
34%
Cisplatin
32%
Docetaxel
32%
Ramucirumab
29%
Phase II Trials
29%
Trastuzumab
24%
Fluoropyrimidine
24%
Immunotherapy
23%
Diseases
23%
Paclitaxel
18%
Capecitabine
18%
Biological Marker
17%
Cetuximab
16%
Adverse Event
15%
Progression Free Survival
14%
Nivolumab
13%
Epidermal Growth Factor Receptor 2
12%
Taxane
11%
Squamous Cell Carcinoma
11%
Gamma Urogastrone
11%
Epidermal Growth Factor Receptor
11%
Disease Free Survival
10%
Esophageal Squamous Cell Carcinoma
9%
Pembrolizumab
9%
Stomach Adenocarcinoma
9%
Polyethylene Terephthalate
9%
Monotherapy
9%
Survival Rate
9%
Ipilimumab
8%
Placebo
8%
Irinotecan
8%
Clinical Trial
8%
Esophageal Adenocarcinoma
8%
Esophagus Cancer
8%
First-Line Chemotherapy
7%
Esophagus Carcinoma
7%
Metastatic Colorectal Cancer
7%
Chemoradiation Therapy
7%
Chemotherapy Induced Nausea and Vomiting
6%
Remission
6%
Skin Toxicity
6%
Esophagus Tumor
6%
Medicine and Dentistry
Adenocarcinoma
80%
Malignant Neoplasm
69%
Abdominal Cancer
56%
Neoplasm
52%
Gastroesophageal Junction
44%
Immunotherapy
32%
Overall Survival
27%
Diseases
24%
Oxaliplatin
23%
Docetaxel
22%
Arm
21%
Trastuzumab
21%
Polyethylene Terephthalate
19%
Fluorouracil
19%
Neoadjuvant Chemotherapy
18%
Folinic Acid
18%
Biological Marker
18%
Fluoropyrimidine
18%
Cancer
18%
Targeted Therapy
18%
Systemic Therapy
16%
Chemoradiotherapy
16%
Cisplatin
14%
Clinical Trial
13%
Nivolumab
13%
Pembrolizumab
12%
Elderly Patient
12%
Ramucirumab
12%
Quality of Life
12%
Esophageal Cancer
11%
Metastatic Carcinoma
11%
Progression Free Survival
11%
FOLFOX
11%
Phase II Trials
11%
Metastatic Colorectal Cancer
11%
Positron Emission Tomography
11%
Disease Free Survival
9%
Programmed Death-Ligand 1
9%
Ipilimumab
9%
Stomach Carcinoma
9%
Carcinoma
9%
Paclitaxel
8%
Survival Rate
8%
Monotherapy
8%
Esophageal Adenocarcinoma
8%
Preoperative Chemotherapy
8%
Programmed Cell Death
7%
Esophagus
7%
Stomach Adenocarcinoma
7%
Placebo
7%
